LEO Pharma is among the world's leading companies in topical dermatology and parenteral treatment of thromboembolic disorders. We pride ourselves on the results that the dedicated and motivated people at LEO achieve. The creativity, knowledge and experience accumulated in our organisation together with our financial independence are pivotal to our aim of getting safe and efficacious drugs on the market.
Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.
Dermatrends is a skin sciences company with a proprietary technology. Founded in 1993, our scientists have perfected a hydroxide-releasing (HRA) technology. For pharmaceutical applications, our technology enables drugs to permeate the skin at therapeutic levels when applied in a small drug-in-adhesive matrix patch. We have test results demonstrating permeation at therapeutic levels with more than 30 compounds including NSAIDs, PPI's and more. In the cosmetic and dermatology arena, our HRA technology allows us to increase the effectiveness of active ingredients when applied to the skin for a wide variety of applications. Our initial formulation in the anti-aging category delivers an exfoliant that is non-drying and leaves the skin soft and moisturized.
Fujisawa Healthcare is a North American subsidiary of Fujisawa Pharmaceutical Company Ltd., based in Osaka, Japan. Since its founding in 1894, Fujisawa has been a leading manufacturer and marketer in the world,s major markets. With sales of over $2 billion, Fujisawa employs more than 8,000 people worldwide.
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully integrated drug development and manufacturing solutions. At DPT our mission is to improve health and quality of life by providing our healthcare partners the best solutions to their development and manufacturing needs.
DRAXIS Health Inc. is one of Canada's premier specialty pharmaceutical companies. We offer a lively, entrepreneurial and collegial workplace, competitive compensation and excellent benefits. DRAXIS Health Inc. operates in a stable, well respected and satisfying industry well-known for its commitment to improving the delivery of quality healthcare products and services. If you thrive in an entrepreneurial environment where individual contributions to the success of the company are recognized, we welcome you. If you are interested in joining our team, please send us your c.v. via e-mail to cv@draxis.com. You can also send us your c.v. by fax to 514 694-1355; please address your c.v. to the attention of the Human Resources department.
Since 1919, Upsher-Smith Laboratories, Inc. has grown into one of the world's top pharmaceutical companies. This growth is due to our company's quest for Excellence through Innovation. With state-of-the-art facilities located in Minneapolis, Minnesota and Denver, Colorado, we develop, manufacture, and market an array of products that advance human health. Our proven legacy of excellence and ongoing focus on innovation establish a foundation for our continued success. Innovation embodies every aspect of our organization, ensuring excellence through quality, service, and customer satisfaction.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales which enables the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OBGYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies. In November 1991, Bradley became a publicly traded company on the NASDAQ exchange, and listed on the NYSE in May 2003. In 2004, Bradley was ranked tenth on Fortune magazine's list of the 100 Fastest Growing Companies in the United States, and was included on Standard & Poor's SmallCap 600 GICS® Pharmaceuticals Sub-Industry Index.
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on developing and marketing proprietary, innovative medical therapies to the dermatology market. CollaGenex's has a highly-experienced 80-person sales force that is targeting 5,600 dermatologists. In July 2006, CollaGenex launched Oracea® (doxycyline, USP) Capsules 40 mg*, the first FDA-approved systemic product for the treatment of rosacea. The Company also markets Alcortin® (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort® (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. Alcortin and Novacort are marketed by the Company under a Promotion and Cooperation agreement with Primus Pharmaceuticals, Inc. The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. CollaGenex is conducting Phase II clinical trials to evaluate COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea. CollaGenex recently acquired the rights to develop and commercialize becocalcidiol, a patented Vitamin D analogue developed by QuatRx Pharmaceuticals Company, and it is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis. CollaGenex plans to leverage its technology platforms to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties. Based on research that has shown compounds can be created by chemically modifying certain tetracyclines and that these new compounds have properties that may make them effective in treating diseases involving inflammation and/or destruction of the body's connective tissues, CollaGenex is evaluating various chemically modified tetracyclines (so called "IMPACS"Ô compounds because they are Inhibitors of Multiple Proteases And CytokineS) to assess whether they are safe and effective in these applications. In addition, CollaGenex has acquired the SansRosaÔ technology, which consists of a class of compounds that have shown promise in reducing the redness associated with rosacea; becocalcidiol, a patented Vitamin D analogue; and the Restoraderm® technology, a unique, proprietary dermal drug delivery system. Periostat®, Restoraderm® and Oracea® are registered trademarks and IMPACSÔ and SansRosaÔ are trademarks of CollaGenex Pharmaceuticals, Inc. Novacort® and Alcortin® are trademarks of Primus Pharmaceuticals, Inc. All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries. * 30 mg Immediate Release and 10 mg Delayed Release beads.
Auriga Laboratories, Inc. is a specialty pharmaceutical company engaged in the commercialization, licensing, and development of prescription pharmaceutical products. The Company’s products are focused in the respiratory, dermatology central nervous system (CNS) and anti-infective therapeutic categories and are marketed to primary care physicians, pediatricians, dermatologists, urologists, psychiatrists, and rheumatologists. On December 3, 2007, the Company announced its acquisition of a license from Outlook Pharmaceuticals, Inc., to make, distribute, commercialize, market and sell in the United States a new product, Liquadd, indicated for the treatment of attention deficit hyperactivity disorder. On January 7, 2008, the Company announced its acquisition from Middlebrook Pharmaceuticals, Inc. of the right to co-promote Keflex 750 milligrams capsules (cephalexin capsules, USP), to primary care physicians in the United States. (Source: 10KSB)
Taro Pharmaceutical Industries Ltd. (Taro) is a multinational, science-based pharmaceutical company that develops, manufactures and markets prescription and over-the-counter (OTC) pharmaceutical products primarily in the United States, Canada and Israel. It also develops and manufactures active pharmaceutical ingredients (APIs) primarily for use in its finished dosage form products. Its primary areas of focus include topical creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries: Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 20 countries. Taro’s product groups include Amiodarone Hydrochloride, Ammonium Lactate, Carbamazepine and Clobetasol Propionate. (Source: 10-K)
SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets and sells primarily to dermatologists both prescription pharmaceutical products and cosmeceutical products, which are non-prescription skin care products that are dispensed or sold by physicians directly to their patients. The Company has two pharmaceutical products and 19 cosmeceutical products. The Company is developing both a portfolio of additional pharmaceutical products and a number of line extensions for its cosmeceutical products.
Inyx, Inc. is a specialty pharmaceutical company with niche drug-delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania, which conducts Inyx's marketing and distribution activities. Inyx, Inc.'s corporate offices are in New York City.
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel. The Company's research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. Since its acquisition of ForSight Newco II, Inc. (QLT Plug Delivery, Inc.) on October 18, 2007, the Company is also developing an ocular punctal plug drug delivery system. QLT's first commercial product was in the field of photodynamic therapy (PDT), which uses photosensitizers (light activated drugs) in the treatment of disease. The Company's commercial product, Visudyne, utilizes photodynamic therapy (PDT) to treat the eye disease known as wet age related macular degeneration (AMD). In October 2007, QLT Inc. completed the acquisition of ForSight Newco II, Inc.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare-related products. During the year ended December 31, 2007, the Company had three segments: Pharmaceuticals, Nutritionals and ConvaTec. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The other two segments – Nutritionals and ConvaTec – comprised the Company’s Health Care Group. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children’s nutritionals business. The ConvaTec segment consisted of the ostomy, wound and skin care business. On January 7, 2008, the Company completed the sale of its Medical Imaging business to Avista Capital Partners L.P. In August 2008, BMS announced that Nordic Capital Fund VII and Avista Capital Partners completed their acquisition of ConvaTec.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory